Cargando…

QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease

Inflammatory bowel disease (IBD) has been described as an independent risk factor for the development of cardiovascular (CV) disease. Since the QRESEARCH risk estimator version 3 (QRISK3) calculator was recently proposed to assess CV in the general population, our objective was to compare the predic...

Descripción completa

Detalles Bibliográficos
Autores principales: Carrillo-Palau, Marta, Hernández-Camba, Alejandro, Ramos, Laura, Vela, Milagros, Arranz, Laura, Hernández Alvarez-Buylla, Noemi, Alonso-Abreu, Inmaculada, Hernández-Pérez, Anjara, Hernández-Guerra, Manuel, Palazuelos, Camilo, Llorca, Javier, González-Gay, Miguel Á., Ferraz-Amaro, Iván
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464851/
https://www.ncbi.nlm.nih.gov/pubmed/34575213
http://dx.doi.org/10.3390/jcm10184102
_version_ 1784572720268181504
author Carrillo-Palau, Marta
Hernández-Camba, Alejandro
Ramos, Laura
Vela, Milagros
Arranz, Laura
Hernández Alvarez-Buylla, Noemi
Alonso-Abreu, Inmaculada
Hernández-Pérez, Anjara
Hernández-Guerra, Manuel
Palazuelos, Camilo
Llorca, Javier
González-Gay, Miguel Á.
Ferraz-Amaro, Iván
author_facet Carrillo-Palau, Marta
Hernández-Camba, Alejandro
Ramos, Laura
Vela, Milagros
Arranz, Laura
Hernández Alvarez-Buylla, Noemi
Alonso-Abreu, Inmaculada
Hernández-Pérez, Anjara
Hernández-Guerra, Manuel
Palazuelos, Camilo
Llorca, Javier
González-Gay, Miguel Á.
Ferraz-Amaro, Iván
author_sort Carrillo-Palau, Marta
collection PubMed
description Inflammatory bowel disease (IBD) has been described as an independent risk factor for the development of cardiovascular (CV) disease. Since the QRESEARCH risk estimator version 3 (QRISK3) calculator was recently proposed to assess CV in the general population, our objective was to compare the predictive ability of QRISK3 with that of a well-established European CV risk calculator, the Systematic Coronary Risk Assessment (SCORE), to identify the presence of subclinical carotid atherosclerosis in patients with IBD. In all, 186 patients with IBD and 178 controls were recruited. The presence of subclinical atherosclerosis was evaluated by carotid ultrasound to identify carotid plaque and the thickness of the carotid intima-media (cIMT). QRISK3 and SCORE were calculated. The relationship of QRISK3 and SCORE with each other and with the presence of subclinical carotid atherosclerosis (both carotid plaque and cIMT) was studied in patients and controls. SCORE (0.2 (interquartile range 0.1–0.9) vs. 0.4 (0.1–1.4), p = 0.55) and QRISK3 1.7 ((0.6–4.6) vs. 3.0 (1.0–7.8), p = 0.16) absolute values did not differ between patients and controls. QRISK3 and SCORE correlated equally with cIMT within both populations. However, SCORE correlation with cIMT was found to be significantly lower in patients with IBD when compared to controls (Spearman’s Rho 0.715 vs. 0.587, p = 0.034). Discrimination analysis of both calculators with carotid plaque was similar within both populations. Nevertheless, in patients with IBD, QRISK3 showed a trend toward a higher discrimination (QRISK3 area under the curve 0.812 (95%CI 0.748–0.875) vs. SCORE 0.790 (95%CI 0.723–0.856), p = 0.051). In conclusion, QRISK3 discrimination for subclinical atherosclerosis is optimal and equivalent to that of SCORE in IBD patients. However, our findings highlight the role of QRISK3 as an appropriate tool for the assessment of CV risk in patients with IBD.
format Online
Article
Text
id pubmed-8464851
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84648512021-09-27 QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease Carrillo-Palau, Marta Hernández-Camba, Alejandro Ramos, Laura Vela, Milagros Arranz, Laura Hernández Alvarez-Buylla, Noemi Alonso-Abreu, Inmaculada Hernández-Pérez, Anjara Hernández-Guerra, Manuel Palazuelos, Camilo Llorca, Javier González-Gay, Miguel Á. Ferraz-Amaro, Iván J Clin Med Article Inflammatory bowel disease (IBD) has been described as an independent risk factor for the development of cardiovascular (CV) disease. Since the QRESEARCH risk estimator version 3 (QRISK3) calculator was recently proposed to assess CV in the general population, our objective was to compare the predictive ability of QRISK3 with that of a well-established European CV risk calculator, the Systematic Coronary Risk Assessment (SCORE), to identify the presence of subclinical carotid atherosclerosis in patients with IBD. In all, 186 patients with IBD and 178 controls were recruited. The presence of subclinical atherosclerosis was evaluated by carotid ultrasound to identify carotid plaque and the thickness of the carotid intima-media (cIMT). QRISK3 and SCORE were calculated. The relationship of QRISK3 and SCORE with each other and with the presence of subclinical carotid atherosclerosis (both carotid plaque and cIMT) was studied in patients and controls. SCORE (0.2 (interquartile range 0.1–0.9) vs. 0.4 (0.1–1.4), p = 0.55) and QRISK3 1.7 ((0.6–4.6) vs. 3.0 (1.0–7.8), p = 0.16) absolute values did not differ between patients and controls. QRISK3 and SCORE correlated equally with cIMT within both populations. However, SCORE correlation with cIMT was found to be significantly lower in patients with IBD when compared to controls (Spearman’s Rho 0.715 vs. 0.587, p = 0.034). Discrimination analysis of both calculators with carotid plaque was similar within both populations. Nevertheless, in patients with IBD, QRISK3 showed a trend toward a higher discrimination (QRISK3 area under the curve 0.812 (95%CI 0.748–0.875) vs. SCORE 0.790 (95%CI 0.723–0.856), p = 0.051). In conclusion, QRISK3 discrimination for subclinical atherosclerosis is optimal and equivalent to that of SCORE in IBD patients. However, our findings highlight the role of QRISK3 as an appropriate tool for the assessment of CV risk in patients with IBD. MDPI 2021-09-11 /pmc/articles/PMC8464851/ /pubmed/34575213 http://dx.doi.org/10.3390/jcm10184102 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Carrillo-Palau, Marta
Hernández-Camba, Alejandro
Ramos, Laura
Vela, Milagros
Arranz, Laura
Hernández Alvarez-Buylla, Noemi
Alonso-Abreu, Inmaculada
Hernández-Pérez, Anjara
Hernández-Guerra, Manuel
Palazuelos, Camilo
Llorca, Javier
González-Gay, Miguel Á.
Ferraz-Amaro, Iván
QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease
title QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease
title_full QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease
title_fullStr QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease
title_full_unstemmed QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease
title_short QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease
title_sort qrisk3 performance in the assessment of cardiovascular risk in patients with inflammatory bowel disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464851/
https://www.ncbi.nlm.nih.gov/pubmed/34575213
http://dx.doi.org/10.3390/jcm10184102
work_keys_str_mv AT carrillopalaumarta qrisk3performanceintheassessmentofcardiovascularriskinpatientswithinflammatoryboweldisease
AT hernandezcambaalejandro qrisk3performanceintheassessmentofcardiovascularriskinpatientswithinflammatoryboweldisease
AT ramoslaura qrisk3performanceintheassessmentofcardiovascularriskinpatientswithinflammatoryboweldisease
AT velamilagros qrisk3performanceintheassessmentofcardiovascularriskinpatientswithinflammatoryboweldisease
AT arranzlaura qrisk3performanceintheassessmentofcardiovascularriskinpatientswithinflammatoryboweldisease
AT hernandezalvarezbuyllanoemi qrisk3performanceintheassessmentofcardiovascularriskinpatientswithinflammatoryboweldisease
AT alonsoabreuinmaculada qrisk3performanceintheassessmentofcardiovascularriskinpatientswithinflammatoryboweldisease
AT hernandezperezanjara qrisk3performanceintheassessmentofcardiovascularriskinpatientswithinflammatoryboweldisease
AT hernandezguerramanuel qrisk3performanceintheassessmentofcardiovascularriskinpatientswithinflammatoryboweldisease
AT palazueloscamilo qrisk3performanceintheassessmentofcardiovascularriskinpatientswithinflammatoryboweldisease
AT llorcajavier qrisk3performanceintheassessmentofcardiovascularriskinpatientswithinflammatoryboweldisease
AT gonzalezgaymiguela qrisk3performanceintheassessmentofcardiovascularriskinpatientswithinflammatoryboweldisease
AT ferrazamaroivan qrisk3performanceintheassessmentofcardiovascularriskinpatientswithinflammatoryboweldisease